Keenova Therapeutics plc - Common Stock, par value $0.01 per share (MNKTQ)

Q: What does CUSIP G5890A102 represent in this 13F holders report?

CUSIP G5890A102 is the security identifier for MNKTQ - Keenova Therapeutics plc - Common Stock, par value $0.01 per share used to aggregate holder disclosures.

Q: How many institutions held MNKTQ - Keenova Therapeutics plc - Common Stock, par value $0.01 per share in Q1 2023?

44 institutional investors reported MNKTQ - Keenova Therapeutics plc - Common Stock, par value $0.01 per share for Q1 2023. Use the holders table for investor-level position and value details.

CUSIP: G5890A102

Q1 2023 13F Holders as of 31 Mar 2023

Security type / class: Equity / Common Stock, par value $0.01 per share
Total 13F shares: 10,313,801
Total 13F value: $75,218,046
Share change: -10,911
SEC-reported price per share: $7.29
Number of holders: 44
Value change: -$870,603
Number of buys: 19
Number of sells: 20
Shares outstanding: 39,705,355

Security key

G5890A102

Report period

Q1 2023

Institutions

Top holders

MNKTQ full security history Ownership snapshot Full 13F holder table Keenova Therapeutics plc SEC filings Keenova Therapeutics plc company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of MNKTQ - Keenova Therapeutics plc - Common Stock, par value $0.01 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Bracebridge Capital, LLC

Disclosed value leader

Bracebridge Capital, LLC

Comparable rows

15/15

Latest evidence

31 Dec 2022

13F Lead comparable stake: 5.1% Showing 1-6 of 15 holder rows.

Quick read

Bracebridge Capital, LLC leads the comparable SEC ownership view at 5.1%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Bracebridge Capital, LLC's linked filing trail.

Comparable ownership Top 5

Bracebridge Capital, LLC 5.1%

JPMORGAN CHASE & CO 4.2%

Hudson Bay Capital Management LP 2.7%

FEDERATED HERMES, INC. 2.5%

Sculptor Capital LP 1.7%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Bracebridge Capital, LLC	13F Company 13F	5.1%	$15,757,742 2,033,257 shares	—	31 Dec 2022
JPMORGAN CHASE & CO	13F Company 13F	4.2%	$13,066,000 1,686,088 shares	—	31 Dec 2022
Hudson Bay Capital Management LP	13F Company 13F	2.7%	$8,165,152 1,053,568 shares	—	31 Dec 2022
FEDERATED HERMES, INC.	13F Company 13F	2.5%	$7,741,925 998,958 shares	—	31 Dec 2022
Sculptor Capital LP	13F Company 13F	1.7%	$5,383,530 694,649 shares	—	31 Dec 2022
VANGUARD GROUP INC	13F Company 13F	1.6%	$5,035,585 649,753 shares	—	31 Dec 2022

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

10,313,801

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2023 vs Q1 2023 Across Filers

Q1 2023 holders

Holder diff

Investor	Q1 2023 Shares	Q1 2023 Shares	Share Diff	Share Chg %	Q1 2023 value	Q1 2023 value	Value change	Value Chg %